Comparison between ABP 234 and Keytruda® (Pembrolizumab)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514304-14-00

Acronym

20210033

Enrollment

233

Registered

2024-09-25

Start date

2024-10-08

Completion date

Unknown

Last updated

2025-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Austria, Bulgaria, France, Germany, Italy, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026